J&J Hopes To Win Back Prestige Case After Judge Favors Home Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's LifeScan subsidiary plans to appeal a June 21 ruling by a Delaware district court that Home Diagnostics Inc.' s Prestige blood glucose test system does not infringe J&J patents.
You may also be interested in...
Home Diagnostics, Inc. v. J&J Lifescan
U.S. Court of Appeals for the Federal Circuit in Washington, D.C. rules that Home Diagnostics' Prestige glucose monitor did not infringe on patents held by Johnson & Johnson subsidiary Lifescan. April 6 decision upholds earlier finding by U.S. District Court in Wilmington, Delaware. Home Diagnostics pulled the Prestige product from the market in November 1999 and has since introduced the Prestige LX, which uses a significantly different technology from the earlier version, the firm says (1"The Gray Sheet" July 3, 2000, p. 17)
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.